Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

摘要: BACKGROUND: Riluzole 100 mg probably prolongs survival in patients with amyotrophic lateral sclerosis by about two months and the safety of drug is not a major concern. The evidence from randomized controlled trials indicates that taking riluzole survive longer than placebo. beneficial effects are very modest expensive. Adverse relatively minor for most part reversible after stopping drug. has been approved treatment many countries but all. Questions persist its clinical utility because high cost, efficacy concern over adverse effects.OBJECTIVES: To examine prolonging survival, delaying use surrogates (tracheostomy mechanical ventilation) to sustain survival.SEARCH STRATEGY: Search Cochrane Neuromuscular Disease Group Register enquiry authors ...